



U.S. National Library of Medicine  
National Center for Biotechnology Information

**NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Iodohippurate Sodium I 123. [Updated 2023 Oct 15].


**Bookshelf URL:** <https://www.ncbi.nlm.nih.gov/books/>



## Iodohippurate Sodium I 123

Revised: October 15, 2023.

CASRN: 56254-07-0



## Drug Levels and Effects

### Summary of Use during Lactation

Information in this record refers to the use of iodohippurate sodium I 123 (I 123 ortho-iodohippurate; I 123 OIH) as a kidney function diagnostic agent. However, some experts recommend nursing the infant just before administration of the radiopharmaceutical and interrupting breastfeeding for 8 to 12 hours after the dose.[1-3] This recommendation is based on possible contamination with other iodine isotopes, which no longer occurs, so a US Nuclear Regulatory Commission subcommittee has recommended that breastfeeding should be interrupted for only 4 hours after administration of I 123 OIH in doses up to 100 MBq (4 mCi) to a nursing mother.[4] If the mother has expressed and saved milk prior to the examination, she can feed it to the infant

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

during the period of nursing interruption.[1,5] Mothers need not refrain from close contact with their infants after usual clinical doses.[6]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[7]

## Drug Levels

I 123 is a gamma emitter with a photon energy of 159 keV and a physical half-life of 13.1 hours.[4] The effective half-life of I 123 OIH ranges from 3.5 to 5.8 hours.[1,7]

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## References

1. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: Data, quantitative analysis and recommendations. *Nucl Med Commun* 1989;10:15-27. PubMed PMID: 2645546.
2. Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. *Ann ICRP* 2015;44 (2 Suppl ):319-21.
3. International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. Available at: <https://www.iaea.org/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation>
4. Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. Available at: <https://www.nrc.gov/docs/ML1903/ML19038A498.pdf>
5. ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. Available at: <https://www.gov.uk/government/publications/arsac-notes-for-guidance>
6. Mountford PJ, O'Doherty MJ. Exposure of critical groups to nuclear medicine patients. *Appl Radiat Isot* 1999;50:89-111. PubMed PMID: 10028630.
7. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. *J Nucl Med* 2000;41:863-73. PubMed PMID: 10809203.

## Substance Identification

### Substance Name

Iodohippurate Sodium I 123

### CAS Registry Number

56254-07-0

## **Drug Class**

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Iodine Radioisotopes

Diagnostic Agents